Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	USD 0.6242	-1.70%	67,432
15/10/26	USD 0.6350	-0.03%	122,580
14/10/26	USD 0.6352	-6.77%	180,730
13/10/26	USD 0.6813	-8.27%	229,930
12/10/26	USD 0.7427	-2.29%	163,612

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6242USD

Average target price

7.000USD

Spread / Average Target

+1,021.44%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Tempest Therapeutics, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tempest Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 07:00:00 17/10/26 am AEDT			5-day change	1st Jan Change
0.6242 ^USD	-1.70%		-17.88%	-78.25%

15/10	Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director	CI
07/10	Sensorion: Louis J. Arcudi III appointed chief financial officer

Market Cap	10.32M 9.19M 8.5M 7.75M 14.6M 980M 14.87M 102M 40.11M 511M 38.74M 37.92M 1.63B	P/E 2026 *	-0.22x	P/E 2027 *	-0.69x
Enterprise Value	10.32M 9.19M 8.5M 7.75M 14.6M 980M 14.87M 102M 40.11M 511M 38.74M 37.92M 1.63B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	69.93%	Yield 2026 *	-	Yield 2027 *	-

15/10	Tempest Therapeutics, Inc. Announces Appointment of John W. Frederick as Director	CI
07/10	Sensorion: Louis J. Arcudi III appointed chief financial officer
29/09	Tempest Therapeutics, Inc. Announces CFO Changes, Effective September 22, 2026	CI
29/09	Tempest Therapeutics, Inc. Appoints Constance Ames as Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, Effective September 22, 2026	CI
23/09	Tempest Therapeutics, Inc. Announces Appointment of Nancy Freda-Smith to Its Board of Director and Chair of Audit Committee, Effective September 22, 2026	CI
16/09	Top Premarket Gainers	MT
16/09	Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang	MT
15/09	Tempest Therapeutics, Inc. announced that it has received $2.496895 million in funding	CI
12/09	Tempest Therapeutics, Inc. announced that it expects to receive $2.500001 million in funding	CI
25/08	Tempest Therapeutics, Inc. Appoints Nicholas Rossettos as Chief Financial Officer, Effective September 1, 2026	CI
25/08	Tempest Therapeutics, Inc. Announces Executive Changes, Effective September 1, 2026	CI
14/08	Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement	CI

22/01	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
10/04/25	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
14/03/24	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
12/10/23	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23/03/23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT

Tempest Therapeutics, Inc. Stock

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Valuation: Tempest Therapeutics, Inc.

Chart: Tempest Therapeutics, Inc.

Latest news: Tempest Therapeutics, Inc.

Analysts' recommendations: Tempest Therapeutics, Inc.

Press Releases: Tempest Therapeutics, Inc.

News in other languages: Tempest Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Tempest Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

23/09	Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors	AQ
16/09	Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform	AQ
11/09	Tempest Therapeutics Announces Up to $7.5 Million Private Placement	AQ
08/09	Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
14/08	Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ

07/10	Sensorion : Louis J. Arcudi III nommé directeur financier
20/06/24	Aktien New York Ausblick: Weitere Tech-Rekorde - Nasdaq 100 mit 20 000 Punkten

1 day	-1.70%
1 week	-17.88%
Current month	-25.18%
1 month	-48.41%
3 months	-36.06%
6 months	-72.13%
Current year	-78.25%

1 week	0.62	0.78
1 month	0.62	1.09
Current year	0.62	3.15
1 year	0.62	11.13
3 years	0.62	95.16
5 years	0.62	190.84
10 years	0.62	533

Manager	Title	Age	Since
Andrew Fang PRN	Corporate Officer/Principal	-	14/04/2026
Matthew Angel CEO	Chief Executive Officer	45	03/02/2026
Constance Ames DFI	Director of Finance/CFO	40	22/09/2026

Director	Title	Age	Since
Mike Raab CHM	Chairman	61	01/01/2021
Christine Pellizzari BRD	Director/Board Member	58	01/07/2021
Matthew Angel BRD	Director/Board Member	45	03/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/9/26	Nancy Freda-Smith	Free	Director	25,000	0.1854%
31/3/26	Justin Trojanowski	Free	Controller/Auditor	22,000	0.1632%
31/3/26	Nicholas Maestas	Free	Chief Financial Officer	140,000	1.0385%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEMPEST THERAPEUTICS, INC.	-1.70%	-17.88%	-94.37%	-99.29%	10.32M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+42.79%	+64.16%	65B
ARGENX SE	-4.09%	-0.11%	+2.31%	+54.81%	51.19B
LONZA GROUP AG	+0.03%	+5.56%	+10.18%	+41.75%	51.2B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+29.72%	+34.13%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.05%	+112.18%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+258.21%	+421.57%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+15.74%	+53.94%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+31.48%	-1.63%	25.2B
BIONTECH SE	-2.76%	-9.54%	-16.53%	-9.55%	22.03B
Average	-1.83%	-3.29%	+29.56%	+67.21%	37.19B
Weighted average by Cap.	-2.30%	-1.21%	+43.56%	+88.57%

Markets		Quality
Nasdaq	TPST	Delayed
CBOE	TPST	Real-time

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-